NCT06611891RecruitingPhase 3
Evaluation of Somatostatin Receptor Expression in PET 68Ga-DOTATOC in Patients Followed for Metastatic Breast Cancer
Source: ClinicalTrials.gov · Last updated 4 Mar 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
DOTABREAST: Evaluation of Somatostatin Receptor Expression in PET 68Ga-DOTATOC in Patients Followed for Metastatic Breast Cancer This is a prospective, monocentric, non-controlled, non-randomized, open-label, interventional study.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 3
- Study type
- Interventional
- Enrollment
- 25 (estimated)
- First submitted
- 20 Apr 2023
- Start date
- 6 Jan 2025
- Primary completion date
- Oct 2025
- Lead sponsor
- University Hospital, Grenoble
- Diseases
- Metastatic breast cancer
- NCT number
- NCT06611891
What you commit to
- Study type: Interventional · Phase 3
- Planned participants: 25
- From 6 Jan 2025 to the primary completion date, Oct 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study design.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Patients followed or with history of other active neoplastic pathology (including neuroendocrine tumor)
- Known allergy to 68Ga-DOTATOC or its excipients
Other
- Subject refusing to sign the consent to participate
- Minor subject
- Subject excluded from another study
- Persons referred to Articles L1121-5 to L1121-8 of the Public Health Code (CSP)
- Subject cannot be contacted in case of emergency
Who the study is looking for
- Age over 18
- Patients with metastatic breast cancer who have completed at least one first line of systemic therapy for metastatic breast cancer
- Patient labeled on the primary lesion ER+HER2- (20)
- Presence of metastatic liver and bone lesions identifiable with 18F-FDG PET-Scan
- Presence of at least 10 identifiable secondary lesions in 18F-FDG PET-Scan
- No therapeutic change between 18F-FDG PET-Scan and 68Ga-DOTATOC PET-Scan.
- Performing the PET scan with 68Ga-DOTATOC within a maximum of 21 days after the 18F-FDG PET-Scan
- Person affiliated to or benefiting from social security
- Person who has given written informed consent
Age in the registry: 18 years to 99 years · Sex: Female · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| CHU Grenoble Alpes Coordinator of this site? Confirm its status | Grenoble | France | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.